{"DataElement":{"publicId":"6763345","version":"1","preferredName":"Laboratory Procedure Breast Carcinoma Receptor Status Type","preferredDefinition":"The type of breast carcinoma testing used to detect the presence or absence of specific receptor molecules on the surface of a cells in a specimen.","longName":"BR_CA_RECT_STAT_LAB_TP","context":"MCL","contextVersion":"1","DataElementConcept":{"publicId":"6763344","version":"1","preferredName":"Laboratory Procedure Breast Carcinoma Receptor Status","preferredDefinition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._Refers to the presence or absence of specific receptor molecules on the surface of a cells in a specimen.","longName":"2543047v1.0:8069318v1.0","context":"MCL","contextVersion":"1","ObjectClass":{"publicId":"2543047","version":"1","preferredName":"Test","preferredDefinition":"A procedure for critical evaluation; a means of determining the presence, quality, or truth of something.","longName":"C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2262D258-9F2F-4D98-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-16","modifiedBy":"ONEDATA","dateModified":"2006-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"8069318","version":"1","preferredName":"Breast Carcinoma Receptor Status","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.:Refers to the presence or absence of specific receptor molecules on the surface of a cells in a specimen.","longName":"C4872:C94299","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Receptor Status","conceptCode":"C94299","definition":"Refers to the presence or absence of specific receptor molecules on the surface of a cells in a specimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D952B81E-245E-2745-E053-4EBD850A8B16","latestVersionIndicator":"Yes","beginDate":"2022-03-03","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2022-03-03","modifiedBy":"ONEDATA","dateModified":"2022-03-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8957F677-BB65-2203-E053-F662850A0936","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"KNABLEJ","dateModified":"2022-03-03","changeDescription":"3/3/22 jk semantics updated, released as part of quarterly content review and prior reviews with SMEs.  5/20/19 jk created for Initial Diagnosis module; added CSI for diagnosis and surgical therapy.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6763339","version":"1","preferredName":"Breast Carcinoma Receptor Status Type","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._Refers to the presence or absence of specific receptor molecules on the surface of a cells in a specimen._Something distinguishable as an identifiable class based on common qualities.","longName":"6763339v1.0","context":"MCL","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"5","maxLength":"20","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Pending","valueDescription":"Pending","ValueMeaning":{"publicId":"2784518","version":"1","preferredName":"Pending","longName":"2784518","preferredDefinition":"Not yet decided or settled; awaiting conclusion or confirmation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pending","conceptCode":"C53470","definition":"Not yet decided or settled; awaiting conclusion or confirmation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"56EFDF2C-6BD9-3BA3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-09-15","endDate":null,"createdBy":"CURTIST","dateCreated":"2008-09-15","modifiedBy":"DWARZEL","dateModified":"2022-10-03","changeDescription":"Updated VM Short Name to be the Public ID to be consistent with current convention for VM Short Name - DW 10-03-2022","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B3B532C-5838-0617-E053-F662850A8D0D","beginDate":"2019-06-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-13","modifiedBy":"ONEDATA","dateModified":"2019-06-13","deletedIndicator":"No"},{"value":"Not done","valueDescription":"Not Done","ValueMeaning":{"publicId":"4163021","version":"1","preferredName":"Not Done","longName":"4163021","preferredDefinition":"Indicates a task, process or examination that has either not been initiated or not been completed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Done","conceptCode":"C49484","definition":"Indicates a task, process or examination that has either not been initiated or not been completed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2B5E544-9A39-F7D4-E040-BB89AD4312F7","latestVersionIndicator":"Yes","beginDate":"2014-02-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-02-18","modifiedBy":"KUMMEROA","dateModified":"2023-12-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8B3B532C-5842-0617-E053-F662850A8D0D","beginDate":"2019-06-13","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-06-13","modifiedBy":"ONEDATA","dateModified":"2019-06-13","deletedIndicator":"No"},{"value":"Ki-67","valueDescription":"Ki67 Measurement","ValueMeaning":{"publicId":"6422539","version":"1","preferredName":"Ki67 Measurement","longName":"6422539","preferredDefinition":"The determination of the amount of Ki-67 protein present in a sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ki67 Measurement","conceptCode":"C123557","definition":"The determination of the amount of Ki-67 protein present in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7494421F-CDFD-4404-E053-F662850AB142","latestVersionIndicator":"Yes","beginDate":"2018-08-29","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-08-29","modifiedBy":"ONEDATA","dateModified":"2018-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8957A87F-B946-65CF-E053-F662850A3077","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","deletedIndicator":"No"},{"value":"Her2 FISH/Dual ISH","valueDescription":"Human Epidermal Growth Factor Receptor 2 Measurement Fluorescence in Situ Hybridization Dual-probe in Situ Hybridization","ValueMeaning":{"publicId":"6763340","version":"1","preferredName":"Human Epidermal Growth Factor Receptor 2 Measurement Fluorescence in Situ Hybridization Dual-probe in Situ Hybridization","longName":"6763340","preferredDefinition":"The determination of the amount of human epidermal growth factor receptor 2 present in a sample.: A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.: An in situ hybridization assay for HER2/Neu that uses probes for both HER2 and chromosome 17.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Epidermal Growth Factor Receptor 2 Measurement","conceptCode":"C112312","definition":"The determination of the amount of human epidermal growth factor receptor 2 present in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Fluorescence In Situ Hybridization","conceptCode":"C17563","definition":"A physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin. This technique can be used for identification of chromosomal abnormalities and for gene mapping.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Dual-probe in Situ Hybridization","conceptCode":"C159521","definition":"An in situ hybridization assay for HER2/Neu that uses probes for both HER2 and chromosome 17.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8957A87F-B955-65CF-E053-F662850A3077","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8957A87F-B96E-65CF-E053-F662850A3077","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","deletedIndicator":"No"},{"value":"Her2 IHC","valueDescription":"Human Epidermal Growth Factor Receptor 2 Measurement Immunohistochemical Test","ValueMeaning":{"publicId":"6763341","version":"1","preferredName":"Human Epidermal Growth Factor Receptor 2 Measurement Immunohistochemical Test","longName":"6763341","preferredDefinition":"The determination of the amount of human epidermal growth factor receptor 2 present in a sample.: A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Human Epidermal Growth Factor Receptor 2 Measurement","conceptCode":"C112312","definition":"The determination of the amount of human epidermal growth factor receptor 2 present in a sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunohistochemical Test","conceptCode":"C51944","definition":"A diagnostic test in which an antibody is used to link a cellular antigen specifically to a stain that can be seen with a microscope.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8957A87F-B97B-65CF-E053-F662850A3077","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8957A87F-B994-65CF-E053-F662850A3077","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","deletedIndicator":"No"},{"value":"PR status","valueDescription":"Progesterone Receptor Status","ValueMeaning":{"publicId":"5497690","version":"1","preferredName":"Progesterone Receptor Status","longName":"5497690","preferredDefinition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progesterone Receptor Status","conceptCode":"C16149","definition":"Indicates the progesterone receptor level measured in a primary tumor or in metastases. (>=10 is positive if measured in fmols/mg cytosol protein; Otherwise use institutional standards)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DF8E839-845B-2309-E053-F662850A7FBB","latestVersionIndicator":"Yes","beginDate":"2016-10-03","endDate":null,"createdBy":"COLBERTM","dateCreated":"2016-10-03","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8957A87F-B9A8-65CF-E053-F662850A3077","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","deletedIndicator":"No"},{"value":"ER status","valueDescription":"Estrogen Receptor Status","ValueMeaning":{"publicId":"5497689","version":"1","preferredName":"Estrogen Receptor Status","longName":"5497689","preferredDefinition":"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a \"late-onset\" form of breast cancer and for an older woman to have an \"early-onset\" variant of the disease.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Estrogen Receptor Status","conceptCode":"C16150","definition":"The estrogen receptor level measured in a primary tumor or in metastases.  There are essentially two distinct forms of breast cancer, one that tends to have an early onset and is characterized by an ER- status, and one that tends to have a late onset and is characterized by an ER+ status.  However, these two variants tend to overlap with respect to age, so it is possible for a young woman to have a \"late-onset\" form of breast cancer and for an older woman to have an \"early-onset\" variant of the disease.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3DF8E839-8438-2309-E053-F662850A7FBB","latestVersionIndicator":"Yes","beginDate":"2016-10-03","endDate":null,"createdBy":"COLBERTM","dateCreated":"2016-10-03","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8957A87F-B9BD-65CF-E053-F662850A3077","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6763338","version":"1","preferredName":"Breast Carcinoma Receptor Status Type","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.:Refers to the presence or absence of specific receptor molecules on the surface of a cells in a specimen.:Something distinguishable as an identifiable class based on common qualities.","longName":"C4872:C94299:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Receptor Status","conceptCode":"C94299","definition":"Refers to the presence or absence of specific receptor molecules on the surface of a cells in a specimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8957A87F-B91C-65CF-E053-F662850A3077","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"ONEDATA","dateModified":"2019-05-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8957A87F-B92D-65CF-E053-F662850A3077","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"KNABLEJ","dateModified":"2022-03-03","changeDescription":"3/3/22 jk released as part of quarterly content review and prior reviews with SMEs.  5/20/19 jk created for Initial Diagnosis module; added CSI for diagnosis and surgical therapy.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5506112","version":"1","longName":"Breast","context":"MCL","ClassificationSchemeItems":[{"publicId":"6643184","version":"1","longName":"Surgical Therapy","context":"MCL"},{"publicId":"6643181","version":"1","longName":"Initial Diagnosis","context":"MCL"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Receptor Status","type":"Preferred Question Text","description":"Receptor Status","url":null,"context":"MCL"}],"origin":"MCL:Molecular and Cellular Characterization of Screened Lesions","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8955164F-90DE-71E3-E053-F662850A65A9","latestVersionIndicator":"Yes","beginDate":"2019-05-20","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-05-20","modifiedBy":"KNABLEJ","dateModified":"2022-03-03","changeDescription":"3/3/22 jk semantics updated, released as part of quarterly content review and prior reviews with SMEs.  5/20/19 jk created for Initial Diagnosis module; added CSI for diagnosis and surgical therapy.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}